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In page 6, the authors mentioned that they used the outcome proportions observed in a comparative clinical trial of two methods of hormonal contraception in women who became pregnant following EHC. Again, can participants in the comparative clinical trial represent the target population? Participants in clinical trials are usually selected based on inclusive and exclusive criteria.
The effectiveness of a self-administrative contraceptive method like condom and pill in clinical trials is usually higher than that in typical use. Hence the cost-effectiveness may be overestimated in this manuscript. The authors may need to discuss this limitations.
Overall, there are some limitations on the data that this manuscript is used to calculate cost-effectiveness of EHC. The authors need to discuss these limitations adequately.
GENERAL COMMENTS
Since the Abstract is all some read it should say where the study was done, i.e., England p4-29: is UPSI already defined? If not, do so. p4: last 2 sentences are the conclusion so are redundant with it. p5: say methods, not "methodology" p11, para 2: "unintended pregnancies are associated with high rates of prematurity, a very expensive outcome which would make your estimates even more conservative
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Reviewer Name James Trussell Institution and Country Princeton University, USA Please state any competing interests or state 'None declared': None declared.
See the attached letter to the editor on the cost effectiveness of UPA.
This comment is not relevant to our study since we did not examine the cost saving potential of improving access to EHC but rather what changing the intervention for those already accessing EC might look like. Our conclusions are drawn from comparing what providing an alternative method to women already presenting for EHC might confer in economic benefits rather than seeking to attract more users of EHC. On page 12 we have clarified the population of interest to be women' who are already presenting' for EHC Furthermore, the Bayer et al Study that reviewer Trussell comments on is in a different setting to our study i.e. in the US as opposed to the UK. There are vast differences between these two countries in both the funding of healthcare and the provision of emergency contraception. For example, the Bayer study models the pregnancy costs that are incurred from State Medicaid payments; however, Medicaid covers only 40% of pregnant women in the US and only up to 60 days post-partum. In contrast our study looks at costs that were actually incurred by the UK NHS in 2011 by 97% of pregnant women and for all live births up to a year post delivery.
Reviewer Name Yan Che Institution and Country Shanghai Institute of Planned Parenthood Research, China Please state any competing interests or state 'None declared': None declared
The authors applied the outcomes in clinical trials of EHC to calculate the cost of an unintended pregnancy. It may be needed to discuss how much the participants in these clinical trials represent their target population.
The randomised controlled comparative studies analysed data on almost 3500 women from centres in US and Europe including 10 centres in UK and 1 in Ireland. This clarification has been inserted on page 4. The clinical trial population excluded women whose partners were sterilised or who were taking hormonal contraception but we do not know the characteristics of those who declined to participate so cannot comment further on whether they differ from those who elected to take part. However, since this self-selection bias would exist in both arms, it is unlikely to affect the magnitude of the difference between the two groups.
Women who become pregnant after taking EHC may abort the pregnancy spontaneously or by choice or continue to deliver the baby. This outcome is unlikely to be affected by whether the woman has participated in a clinical trial for emergency contraception following UPSI. We also use studies published in routine clinical practice and compare the outcomes and implications for these in the sensitivity analysis, shown on page 8 of the manuscript. In 'clinical practice' there are 21% women continuing to delivery as opposed to 17% in 'clinical trial population' which leads to an increase in both medical and social costs. These figures are also outlined in Appendix D.
The effectiveness of a self-administrative contraceptive method like condom and pill in clinical trials is usually higher than that in typical use. Hence the cost-effectiveness may be overestimated in this manuscript. The authors may need to discuss this limitations. This is less likely to be so in the case of emergency contraception since it is a taken as a one-off after exposure to UPSI rather than requiring to be taken on an ongoing and regular basis such as the pill or prior to sex as per the condom. As such EHC is a supplementary method to routine contraception and women who present after UPSI and request EHC are likely to take it. If there is any overestimation of this then it exists in both groups and therefore the incremental cost-effectiveness is less likely to be an overestimation.
Overall, there are some limitations on the data that this manuscript is used to calculate costeffectiveness of EHC. The authors need to discuss these limitations adequately.
We have outlined these in bullet points following the abstract and elaborated on the main points further in the Discussion section starting on page 11
Reviewer Name Prof Philip D. Darney Institution and Country University of California, San Francisco, USA Please state any competing interests or state 'None declared': none declared.
Since the Abstract is all some read it should say where the study was done, i.e., England Thank you we have inserted 'in England' in the setting p4-29: is UPSI already defined? If not, do so. This is defined in the abstract on page 2 but we have redefined it on the first use in main text on page 4 p4: last 2 sentences are the conclusion so are redundant with it. We have deleted the last sentence as requested p5: say methods, not "methodology" We have changed this heading to 'methods' p11, para 2: "unintended pregnancies are associated with high rates of prematurity, a very expensive outcome which would make your estimates even more conservative Thank you -we have inserted a sentence to this effect at the end of paragraph 3. 
GENERAL COMMENTS
I understand that it is difficult to identify the difference of the characteristics between women who participated in the trials and those who didn't. In general, participants in a clinical trial are 'healthier' than general population because 'unhealthy' subjects are usually excluded from the trial. Self-selection bias is less likely to affect RR (relative risk) or OR (odds ratio), but very likely to affect rate or proportion distribution. My concern for the data of this manuscript is that the proportion of pregnant outcomes in clinical trials may differ from that in general population. The authors mentioned 'In clinical practice there are 21% women continuing to delivery as opposed to 17% in 'clinical trial population'. This is just the case, although the conclusion may not be changed due to this limitation.
